Last updated on February 2018

The PRONTO Study a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Brief description of study

This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who had a hematologic response to previous treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and have persistent cardiac dysfunction.

Clinical Study Identifier: NCT02632786

Contact Investigators or Research Sites near you

Start Over

Michael Rosenzweig, MD

City of Hope
Duarte, CA United States

Michaela Liedtke, MD

Stanford Cancer Institute (SCI)
Stanford, CA United States

Tara Gregory, MD

Colorado Blood Cancer Institute
Denver, CO United States

Taimur Sher, MD

Mayo Clinic
Jaksonville, FL United States

Cara Rosenbaum, MD

University of Chicago Medicine
Chicago, IL United States

Rafat Abonour, MD

Indiana University Simon Cancer Center
Indianapolis, IN United States

Raymond Comenzo, MD

Tufts Medical Center
Boston, MA United States

Vaishali Sanchorawala, MD

Boston University School of Medicine
Boston, MA United States

Jeffrey Zonder, MD

Karmanos Cancer Institute
Detroit, MI United States

Morie Gertz, MD

Mayo Clinic - Minnesota
Rochester, MN United States

Heather Landau, MD

Memorial Sloan-Kettering Cancer Center
New York, NY United States

Cristina Gasparetto, MD

Duke University Medical Center
Durham, NC United States

Jason Valent, MD

The Cleveland Clinic
Cleveland, OH United States

Stephen Heitner, MD

Oregon Health & Science University
Portland, OR United States

Brendan Weiss, MD

Hospital of the University of Pennsylvania
Philadelphia, PA United States

Stacey Goodman, MD

Vanderbilt University Medical Center
Nashville, TN United States

Hans Lee, MD

University of Texas; MD Anderson Cancer Center
Houston, TX United States

Edward Libby, MD

University of Washington/Seattle Cancer Care Alliance
Seattle, WA United States

Anita D'Souza, MD

Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital
Milwaukee, WI United States

Fiona Kwow, MD

Westmead Hospital
Sydney, Australia

Peter Molle, MD

The University of Queensland - Princess Alexandra Hospital (PAH)
Woolloongabba, Australia

Simon Gibbs, MD

Eastern Health (Box Hill Hospital)
Box Hill, Australia

Hermine Agis, MD

Medizinische Universit t Wien, Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria

Arnaud Jaccard, MD

H pital Dupuytren - CHU Limoges
Limoges, France

Sylvain Choquet, MD

H pital Piti -Salp tri re
Paris, France

Lionel Karlin, MD

Hopitaux Lyon Sud
Pierre-Benite Cedex, France

Olivier Decaux, MD

CHU Rennes, Service de Medecine Interne
Rennes Cedex 2, France

Axel Nogai, MD

Berlin, Germany

Alexander Carpinteiro, MD

Universit tsklinikum Essen
Essen, Germany

Timon Hansen, MD

Universitatsklinikum Hamburg-Eppendorf (UKE
Hamburg, Germany

Stefan Schoenland, MD

Universitatsklinikum Heidelberg
Heidelberg, Germany

Efstathios Kastritis, MD

Alexandra General Hospital of Athens
Athens, Greece

Anargyros Symeonidis, MD

University Hospital of Patras
Patras, Greece

Moshe Gatt, MD

Hadassah University Medical Center
Jerusalem, Israel

Giampaolo Merlini, MD

Policlinica San Matteo
Pavia, Italy

Joan Blade, MD

Hospital Clinic de Barcelona
Barcelona, Spain

Isabel Krsnik, MD

Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Spain

Guy Pratt, MD

Centre for Clinical Haematology
Birmingham, United Kingdom

Ashutosh Wechalekar, MD

The Royal Free London NHS Foundation Trust - The Royal Free Hospital
London, United Kingdom

Matthew Jenner, MD

Southampton General Hospital
Southampton, United Kingdom